BioSpace News Archive

exoASO™-STAT6 mediated genetic reprogramming of tumor associated macrophages results in potent single-agent anti-tumor activity in multiple preclinical models; IND submission planned for H2 2021

TCR2 Therapeutics Inc. announced that clinical and translational data from the dose escalation portion of the Company’s Phase 1/2 clinical trial of gavo-cel in patients with treatment refractory mesothelin-expressing solid tumors will be presented at the American Association for Cancer Research Virtual Annual Meeting

Translational analysis of patients that do not respond to PD-(L)1 inhibitors show high pretreatment intratumoral LILRB2 expression relative to an IFNγ gene signature

Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, announced the presentation of new preclinical data on AO-176 in pediatric acute lymphoblastic leukemia during a late-breaking poster presentation at the AACR Annual Meeting 2021.

Agenus, an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, presented new clinical data on AGEN1181, its next-generation anti-CTLA-4 antibody, at the American Association for Cancer Research Annual Meeting from April 10 - 15, 2021.

Initial safety, pharmacokinetic and pharmacodynamic data from the ongoing Phase 1/2 clinical trial for KB-0742 expected in fourth quarter of 2021

KT-413-mediated degradation of IRAK4 and IMiD substrates has synergistic effect on MYD88-NFkB and IRF4-Type 1 Interferon pathways resulting in superior antitumor activity in MYD88-mutant DLBCL models compared to IMiDs or selective IRAK4 targeting alone

Preclinical data show the utility of Gennao’s proprietary first-in-class monoclonal antibody 3E10-D31N (GMABD31N), a cell penetrating antibody, to non-covalently bind to and systemically deliver therapeutic levels of multiple types of nucleic acid payloads to cells in vitro and tumors in vivo

MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced presentations at the American Association for Cancer Research Annual Meeting, taking place April 10-15, 2021.

Vincerx Pharma, Inc. is a biopharmaceutical company aspiring to address the unmet medical needs of cancer patients through paradigm-shifting therapeutics.